GoodRx (GDRX) announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk (NVO), a new introductory cash price of $199 per month for Ozempic and Wegovy injection pens, available to GoodRx users.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month
- GoodRx price target lowered to $5 from $6 at JPMorgan
- GoodRx price target lowered to $6 from $7 at TD Cowen
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China